Alzheimer's Research & Therapy | Most Viewed

Submit a manuscript Register Contact us Follow us on Twitter

Explore journal

Advertisement

Articles

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1. 2928 Accesses	Research The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta, Dave Schubert Alzheimer's Research & Therapy 2013, 5:25 (14 May 2013) Abstract \| Provisional PDF \| PubMed \| Editor’s summary Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
	2. 1363 Accesses	Research Neuroprotective effects of D-Ala²GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model Emilie Faivre, Christian Hölscher Alzheimer's Research & Therapy 2013, 5:20 (19 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.
	3. 1156 Accesses	Research Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models Robyn M Loureiro, Jo Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk, Barbara Tate Alzheimer's Research & Therapy 2013, 5:19 (18 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.
	4. 1063 Accesses	Review 5-HT₆receptors and Alzheimer's disease María Ramírez Alzheimer's Research & Therapy 2013, 5:15 (22 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT₆ receptor compounds, resulting in 5-HT₆-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).
	5. 903 Accesses	Review Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker, Allan I Levey Alzheimer's Research & Therapy 2013, 5:21 (29 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.
	6. 873 Accesses	Review Advances in blood-based protein biomarkers for Alzheimer's disease Lorraine Clark, Thomas Kodadek Alzheimer's Research & Therapy 2013, 5:18 (9 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.
	7. 777 Accesses	Review Alcohol-related dementia: an update of the evidence Nicole J Ridley, Brian Draper, Adrienne Withall Alzheimer's Research & Therapy 2013, 5:3 (25 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ridley and colleagues review the commonality between alcohol-related dementia and alcohol-induced persisting amnestic syndrome in a clinical setting and discuss recommendations for the diagnosis and management of alcohol-related cognitive impairment.
	8. 773 Accesses	Research Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad, Frank Tennigkeit Alzheimer's Research & Therapy 2010, 2:24 (26 August 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central
	9. 768 Accesses	Review Modeling Alzheimer's disease with non-transgenic rat models Laurent Lecanu, Vassilios Papadopoulos Alzheimer's Research & Therapy 2013, 5:17 (1 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.
	10. 571 Accesses	Review DNA-dependent protein kinase and DNA repair: relevance to Alzheimer's disease Jyotshna Kanungo Alzheimer's Research & Therapy 2013, 5:13 (8 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Jyotshna Kanungo discusses possible mechanisms for the role of DNA-dependent protein kinase (DNA-PK) in neurodegeneration leading to Alzheimer's disease.
	11. 524 Accesses	Review Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems Douglas Galasko, Todd E Golde Alzheimer's Research & Therapy 2013, 5:10 (7 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Editors-in-Chief Douglas Galasko and Todd Golde introduce a new special series on Peripheral Biomarkers by providing an overview of key concepts relating to Alzheimer’s disease (AD) plasma, serum and blood biomarker studies.
	12. 502 Accesses	Debate Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease? Harald Hampel, Simone Lista Alzheimer's Research & Therapy 2013, 5:11 (18 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Have we learnt all we need to know from genetic studies in Alzheimer's disease (AD)? Harald Hampel and Simone Lista argue that genetics is not over in AD research, in fact it is more at the beginning than at the end.
	13. 431 Accesses	Research Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte, David Wilkinson Alzheimer's Research & Therapy 2013, 5:6 (21 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Combination treatment with memantine added to donepezil provides significant benefits to moderate and moderate-to-severe Alzheimer's disease patients in meta-analyses of data from two 24-week, randomised, double-blind, placebo-controlled trials.
	14. 424 Accesses	Research Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth, Alan J Lerner, The Alzheimer's Disease Neuroimaging Initiative Alzheimer's Research & Therapy 2013, 5:14 (6 March 2013) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Conversion rates of mild cognitive impairment patients at high risk for progression to Alzheimer's disease (AD) were identified using a novel statistical method based on partially ordered set (poset) models.
	15. 421 Accesses	Research The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection Wolfgang W Quitschke, Nicole Steinhauff, Jean Rooney Alzheimer's Research & Therapy 2013, 5:16 (28 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Biweekly intravenous curcuminoid injections at high concentration reduced the plaque load in transgenic Alzheimer's mice to 70% of the control value, but are rapidly metabolised to undetectable levels within 20 minutes.
	16. 380 Accesses	Commentary Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease Suzanne B Hendrix, Kathleen A Welsh-Bohmer Alzheimer's Research & Therapy 2013, 5:22 (15 May 2013) Abstract \| Full text \| PDF \| PubMed
	17. 367 Accesses	Letter Plasma tau levels in Alzheimer's disease Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansson Alzheimer's Research & Therapy 2013, 5:9 (28 March 2013) Abstract \| Full text \| PDF \| PubMed
	18. 360 Accesses	Commentary Mild traumatic brain injury: a risk factor for neurodegeneration Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski, Ann C McKee Alzheimer's Research & Therapy 2010, 2:18 (25 June 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary Head trauma can lead to progressive neurodegeneration and further study of this risk factor could help us improve prevention and treatment strategies for other neurodegenerative diseases.
	19. 350 Accesses	Research ¹⁸F-florbetaben Aβ imaging in mild cognitive impairment Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger, Christopher C Rowe Alzheimer's Research & Therapy 2013, 5:4 (16 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Higher levels of amyloid-β deposition, measured using 18F-florbetaben imaging, was associated with more severe memory loss in mild cognitive impairment (MCI) patients, proving its utility in early MCI diagnosis.
	20. 343 Accesses	Research Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study John M Ringman, Sally A Frautschy, Edmond Teng, Aynun N Begum, Jenny Bardens, Maryam Beigi, Karen H Gylys, Vladimir Badmaev, Dennis D Heath, Liana G Apostolova, Verna Porter, Zeba Vanek, Gad A Marshall, Gerhard Hellemann, Catherine Sugar, Donna L Masterman, Thomas J Montine, Jeffrey L Cummings, Greg M Cole Alzheimer's Research & Therapy 2012, 4:43 (29 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Oral curcumin did not lead to changes in cognitive examinations or plasma biomarker levels in a 24-week randomized, double blind, placebo-controlled study in patients with Alzheimer disease (AD).
	21. 317 Accesses	Review Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker Jon B Toledo, Leslie M Shaw, John Q Trojanowski Alzheimer's Research & Therapy 2013, 5:8 (8 March 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Toledo, Shaw and Trojanowski review cross-sectional and longitudinal studies of plasma Aβ as a blood-based biomarker for Alzheimer's disease (AD), discussing its potential as a cost effective and non-invasive diagnostic tool.
	22. 299 Accesses	Research Predicting progression of Alzheimer's disease Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby, Wenyaw Chan Alzheimer's Research & Therapy 2010, 2:2 (23 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Baseline cognitive assessments of probable Alzheimer’s disease patients can help predict future performance in cognition and activities of daily living, and should be considered when designing clinical trials in Alzheimer’s disease.
	23. 291 Accesses	Research Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains Brenda D Moore, Paramita Chakrabarty, Yona Levites, Tom L Kukar, Ann-Marie Baine, Tina Moroni, Thomas B Ladd, Pritam Das, Dennis W Dickson, Todd E Golde Alzheimer's Research & Therapy 2012, 4:18 (23 May 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Extensive overlapping between amyloid β (Aβ) levels found in pathological ageing (PA) and Alzheimer's disease (AD) brains indicates that PA represents a prodromal stage of AD or resistance to toxic effects of Aβ.
	24. 290 Accesses	Review Cognitive reserve, cortical plasticity and resistance to Alzheimer's disease Margaret M Esiri, Steven A Chance Alzheimer's Research & Therapy 2012, 4:7 (1 March 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Esiri and Chance discuss the impact of epidemiological factors on cognitive reserve and cortical plasticity, which act as preventative factors against cognitive decline and the development of Alzheimer's disease (AD) in the elderly.
	25. 277 Accesses	Research Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell, Randi Fain Alzheimer's Research & Therapy 2013, 5:12 (21 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Donepezil 23 mg/day provides significant benefits over 10 mg/day across a range of cognitive domains in patients with moderate to severe Alzheimer's disease, especially in the language domain.
	26. 268 Accesses	Review Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease Leonel T Takada, Sharon J Sha Alzheimer's Research & Therapy 2012, 4:38 (3 October 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Takada and Sha review the neuropsychiatric features of chromosome 9p-linked frontotemporal dementia (FTD) and the risk that some C9orf72 mutation carriers may be misdiagnosed with primary psychiatric conditions.
	27. 254 Accesses	Commentary Assessment of psychiatric changes in C9ORF72 frontotemporal dementia Michael Hornberger Alzheimer's Research & Therapy 2012, 4:49 (24 December 2012) Abstract \| Full text \| PDF \| PubMed
	28. 244 Accesses	Research Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease Guriqbal S Basi, Susanna Hemphill, Elizabeth F Brigham, Anna Liao, Danielle L Aubele, Jeanne Baker, Robin Barbour, Michael Bova, Xiao-Hua Chen, Michael S Dappen, Tovah Eichenbaum, Erich Goldbach, Jon Hawkinson, Rose Lawler-Herbold, Kang Hu, Terence Hui, Jacek J Jagodzinski, Pamela S Keim, Dora Kholodenko, Lee H Latimer, Mike Lee, Jennifer Marugg, Matthew N Mattson, Scott McCauley, James L Miller, Ruth Motter, Linda Mutter, Martin L Neitzel, Huifang Ni, Lan Nguyen et al. Alzheimer's Research & Therapy 2010, 2:36 (29 December 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary An amyloid precursor protein selective gamma-secretase inhibitor demonstrates selectivity for inhibiting Amyloid beta production in Alzheimer’s disease transgenic mice and needs to be corroborated in wild-type mice.
	29. 234 Accesses	Research CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques Eloise H Kok, Teemu Luoto, Satu Haikonen, Sirkka Goebeler, Hannu Haapasalo, Pekka J Karhunen Alzheimer's Research & Therapy 2011, 3:12 (5 April 2011) Abstract \| Full text \| PDF \| PubMed \| 1 comment \| Editor’s summary CLU, CR1 and PICALM genes are not strongly related to senile plaque prevalence, or at all to neurofibrillary tangles, and most likely do not affect the development of these Alzheimer’s disease (AD) lesions.
	30. 220 Accesses	Review Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss, Sandra E Black Alzheimer's Research & Therapy 2013, 5:1 (9 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Lam and colleagues review the different subtypes of Alzheimer's disease (AD), discussing the need for personalized AD medicine and the potential for targeting specific AD subtypes in future clinical trials.
	31. 218 Accesses	Editorial The C9ORF72 mutation brings more answers and more questions Bruce L Miller Alzheimer's Research & Therapy 2013, 5:7 (18 February 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Bruce Miller, Guest Editor of the special series: The new FTD mutation on chromosome 9, discusses the C9ORF72 mutation associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis.
	32. 218 Accesses	Commentary Herbal therapy: a new pathway for the treatment of Alzheimer's disease Jinzhou Tian, Jing Shi, Xuekai Zhang, Yongyan Wang Alzheimer's Research & Therapy 2010, 2:30 (22 October 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| 1 comment \| Editor’s summary On the basis of current evidence, Tian and colleagues discuss whether herbal therapy could be a novel pathway to treat Alzheimer’s disease (AD) and the implications of these results on future therapy development.
	33. 212 Accesses	Review Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems Sally Hunter, Carol Brayne Alzheimer's Research & Therapy 2012, 4:10 (13 April 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Hunter and Brayne build a map, modelling relationships between the amyloid precursor protein (APP) and its proteolytic fragments with other neuronal systems and discussing alternative perspectives for its role in Alzheimer's disease progression.
	34. 200 Accesses	Meeting report Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery Rachel F Lane, Penny A Dacks, Diana W Shineman, Howard M Fillit Alzheimer's Research & Therapy 2013, 5:5 (4 February 2013) Abstract \| Full text \| PDF \| PubMed
	35. 198 Accesses	Review Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy Elina Zotova, James AR Nicoll, Raj Kalaria, Clive Holmes, Delphine Boche Alzheimers Res Ther 2010, 2:1 (22 January 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Zotova et al. review the immune processes involved in Alzheimer’s disease pathogenesis and highlight the importance of addressing neuro-immune interactions when devising therapeutic strategies.
	36. 194 Accesses	Research Predictors of long-term cognitive outcome in Alzheimer's disease Carina Wattmo, Åsa K Wallin, Elisabet Londos, Lennart Minthon Alzheimer's Research & Therapy 2011, 3:23 (20 July 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Clinical predictors of a more favorable longitudinal outcome in Alzheimer's disease include male gender, older age, absence of the apolipoprotein E e4 allele, treatment with non-steroidal anti-inflammatory drugs or a higher mean dose of cholinesterase inhibitor.
	37. 186 Accesses	Commentary Dementia: a global health priority - highlights from an ADI and World Health Organization report Marc Wortmann Alzheimer's Research & Therapy 2012, 4:40 (21 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Marc Wortmann, Executive Director of Alzheimer's Disease International, provides a special commentary explaining the importance of World Alzheimer Reports and the need to create national Alzheimer Plans to provide frameworks for action.
	38. 183 Accesses	Research Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice Vjera A Holthoff, Steven Ferris, Ralf Ihl, Philippe Robert, Bengt Winblad, Serge Gauthier, Kati Sternberg, Frank Tennigkeit Alzheimer's Research & Therapy 2011, 3:27 (14 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a valid and reliable instrument to aid medical practitioners in the routine assessment of the severity of Alzheimer's disease symptoms and disease progression.
	39. 182 Accesses	Research Dystrophic neurites express C9orf72 in Alzheimer's disease brains Jun-ichi Satoh, Hiroko Tabunoki, Tsuyoshi Ishida, Yuko Saito, Kunimasa Arima Alzheimer's Research & Therapy 2012, 4:33 (16 August 2012) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary C9orf72 and UBQLN-1 expression in a cluster of dystrophic neurites in senile plaques in Alzheimer's disease brains suggests C9orf72 has a role in the process of neurodegeneration.
	40. 182 Accesses	Review Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Randall J Bateman, Paul S Aisen, Bart De Strooper, Nick C Fox, Cynthia A Lemere, John M Ringman, Stephen Salloway, Reisa A Sperling, Manfred Windisch, Chengjie Xiong Alzheimer's Research & Therapy 2011, 3:1 (6 January 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Trials in autosomal-dominant Alzheimer’s disease (ADAD) are important in order for us to study individuals destined to develop the clinical disease and may yield breakthroughs in the treatment of sporadic AD.
	41. 181 Accesses	Review Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology? Amanda N Sacino, Benoit I Giasson Alzheimer's Research & Therapy 2012, 4:48 (17 December 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Sacino and Giasson review evidence that a self-promoting prion-like mechanism may contribute to the spread and progression of alpha-synuclein pathology in Parkinson’s disease and other synucleinopathies, calling for further study.
	42. 181 Accesses	Review Role of structural MRI in Alzheimer's disease Prashanthi Vemuri, Clifford R Jack Alzheimer's Research & Therapy 2010, 2:23 (31 August 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Structural MRI (sMRI) plays many roles as an Alzheimer’s disease (AD) biomarker and is of both prognostic and diagnostic value, but further work is needed in order to integrate it with other clinical measures.
	43. 180 Accesses	Review Examining the mechanisms that link β-amyloid and α-synuclein pathologies Samuel E Marsh, Mathew Blurton-Jones Alzheimer's Research & Therapy 2012, 4:11 (30 April 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Marsh and Blurton-Jones review evidence suggesting β-amyloid (Aβ) and α-synuclein (α-syn) interact synergistically to enhance aggregation and accelerate cognitive decline, and propose potential mechanistic links between Aβ and α-syn pathologies.
	44. 176 Accesses	Research Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions Colin J Mahoney, Laura E Downey, Gerard R Ridgway, Jon Beck, Shona Clegg, Melanie Blair, Sarah Finnegan, Kelvin K Leung, Tom Yeatman, Hannah Golden, Simon Mead, Jonathan D Rohrer, Nick C Fox, Jason D Warren Alzheimer's Research & Therapy 2012, 4:41 (24 September 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Longitudinal neuropsychological and neuroimaging data on a cohort of patients with pathological repeat expansions in C9ORF72 is assessed, demonstrating longitudinal biomarkers for tracking the evolution of the C9ORF72 mutation phenotype.
	45. 177 Accesses	Review Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies Diana W Shineman, Guriqbal S Basi, Jennifer L Bizon, Carol A Colton, Barry D Greenberg, Beth A Hollister, John Lincecum, Gabrielle G Leblanc, Linda (Bobbi) H Lee, Feng Luo, Dave Morgan, Iva Morse, Lorenzo M Refolo, David R Riddell, Kimberly Scearce-Levie, Patrick Sweeney, Juha Yrjänheikki, Howard M Fillit Alzheimer's Research & Therapy 2011, 3:28 (28 September 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Shineman and colleagues review the contribution of animal models to the understanding of biological mechanisms in Alzheimer's disease (AD) and how the translation of these models to human clinical trials might be improved.
	46. 175 Accesses	Research Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action Patrick D Roberts, Athan Spiros, Hugo Geerts Alzheimer's Research & Therapy 2012, 4:50 (26 November 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Computational analysis of the pathology and mechanisms of drug action in Alzheimer's disease may improve clinical success rates by addressing the translational gap between preclinical animal models and clinical outcomes.
	47. 173 Accesses	Review Dementia prevention: current epidemiological evidence and future perspective Francesca Mangialasche, Miia Kivipelto, Alina Solomon, Laura Fratiglioni Alzheimer's Research & Therapy 2012, 4:6 (13 February 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Mangialasche and colleagues address current epidemiological research and intervention studies to identify promising preventative strategies for Alzheimer's disease (AD) and dementia; considering the need for randomized controlled trials to confirm these findings.
	48. 173 Accesses	Research Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application Carina Wattmo, Erik Jedenius, Kaj Blennow, Åsa K Wallin Alzheimer's Research & Therapy 2013, 5:2 (3 January 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary High compliance to treatment with cholinesterase inhibitor galantamine was seen in a clinical study of patients with Alzheimer's disease (AD), with plasma concentration correlating strongly to dosage.
	49. 171 Accesses	Review Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases Todd E Golde, Victor M Miller Alzheimers Res Ther 2009, 1:5 (12 October 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Golde and Miller propose an integrative hypothesis that provides new insights into how a variety of misfolded protein aggregates can result in neurodegeneration.
	50. 167 Accesses	Research Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial François Piette, Joël Belmin, Hélène Vincent, Nicolas Schmidt, Sylvie Pariel, Marc Verny, Caroline Marquis, Jean Mely, Laurence Hugonot-Diener, Jean-Pierre Kinet, Patrice Dubreuil, Alain Moussy, Olivier Hermine Alzheimer's Research & Therapy 2011, 3:16 (19 April 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary The selective oral tyrosine kinase inhibitor, masitinib, administered as an adjunctive therapy, slows the rate of cognitive decline in Alzheimer’s disease (AD) although further studies are needed to investigate its efficacy and safety.